{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:10:19Z","timestamp":1782252619648,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100010211","name":"Education Department of Jilin Province","doi-asserted-by":"publisher","award":["JJKH20221089KJ"],"award-info":[{"award-number":["JJKH20221089KJ"]}],"id":[{"id":"10.13039\/501100010211","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005227","name":"Jilin Department of Health","doi-asserted-by":"publisher","award":["2019SRCJ008"],"award-info":[{"award-number":["2019SRCJ008"]}],"id":[{"id":"10.13039\/501100005227","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s12026-024-09454-z","type":"journal-article","created":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T03:01:56Z","timestamp":1706324516000},"page":"503-511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rituximab alleviates pediatric systemic lupus erythematosus associated refractory immune thrombocytopenia: a case-based review"],"prefix":"10.1007","volume":"72","author":[{"given":"Fangxin","family":"Mu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3725-8067","authenticated-orcid":false,"given":"Qiaoyan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,27]]},"reference":[{"issue":"9","key":"9454_CR1","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nrrheum.2010.121","volume":"6","author":"S Kamphuis","year":"2010","unstructured":"Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol. 2010;6(9):538\u201346.","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"9454_CR2","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","volume":"113","author":"F Rodeghiero","year":"2009","unstructured":"Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386\u201393.","journal-title":"Blood"},{"issue":"1 Suppl 2","key":"9454_CR3","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/j.seminhematol.2008.12.005","volume":"46","author":"DB Cines","year":"2009","unstructured":"Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol. 2009;46(1 Suppl 2):S2-14.","journal-title":"Semin Hematol"},{"key":"9454_CR4","doi-asserted-by":"crossref","first-page":"613192","DOI":"10.3389\/fmed.2021.613192","volume":"8","author":"A Schifferli","year":"2021","unstructured":"Schifferli A, Cavalli F, Godeau B, et al. Understanding immune thrombocytopenia: looking out of the box. Front Med (Lausanne). 2021;8:613192.","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"9454_CR5","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1177\/0961203313485489","volume":"22","author":"B Jovancevic","year":"2013","unstructured":"Jovancevic B, Lindholm C, Pullerits R. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature. Lupus. 2013;22(7):664\u201374.","journal-title":"Lupus"},{"key":"9454_CR6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jpeds.2018.01.045","volume":"196","author":"O Harry","year":"2018","unstructured":"Harry O, Yasin S, Brunner H. Childhood-onset systemic lupus erythematosus: a review and update. J Pediatr. 2018;196:22\u201330.","journal-title":"J Pediatr."},{"issue":"23","key":"9454_CR7","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829\u201366.","journal-title":"Blood Adv"},{"key":"9454_CR8","doi-asserted-by":"crossref","first-page":"102887","DOI":"10.1016\/j.jaut.2022.102887","volume":"132","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Cheng Y, Ma S, et al. Systemic lupus erythematosus-complicating immune thrombocytopenia: from pathogenesis to treatment. J Autoimmun. 2022;132:102887.","journal-title":"J Autoimmun"},{"issue":"7","key":"9454_CR9","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/rheumatology\/kel010","volume":"45","author":"M Kuwana","year":"2006","unstructured":"Kuwana M, Kaburaki J, Okazaki Y, et al. Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2006;45(7):851\u20134.","journal-title":"Rheumatology (Oxford)"},{"key":"9454_CR10","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1038\/ncomms8737","volume":"6","author":"J Li","year":"2015","unstructured":"Li J, van der Wal DE, Zhu G, et al. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nat Commun. 2015;6:7737.","journal-title":"Nat Commun"},{"key":"9454_CR11","doi-asserted-by":"crossref","first-page":"27445","DOI":"10.1038\/srep27445","volume":"6","author":"J Qiu","year":"2016","unstructured":"Qiu J, Liu X, Li X, et al. CD8(+) T cells induce platelet clearance in the liver via platelet desialylation in immune thrombocytopenia. Sci Rep. 2016;6:27445.","journal-title":"Sci Rep"},{"issue":"1","key":"9454_CR12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40164-021-00214-5","volume":"10","author":"Y Chen","year":"2021","unstructured":"Chen Y, Hu J, Chen Y. Platelet desialylation and TFH cells-the novel pathway of immune thrombocytopenia. Exp Hematol Oncol. 2021;10(1):21.","journal-title":"Exp Hematol Oncol"},{"issue":"9","key":"9454_CR13","doi-asserted-by":"crossref","first-page":"102616","DOI":"10.1016\/j.autrev.2020.102616","volume":"19","author":"E Tinazzi","year":"2020","unstructured":"Tinazzi E, Osti N, Beri R, et al. Pathogenesis of immune thrombocytopenia in common variable immunodeficiency. Autoimmun Rev. 2020;19(9):102616.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"9454_CR14","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/bjh.15165","volume":"181","author":"I Nazy","year":"2018","unstructured":"Nazy I, Kelton JG, Moore JC, et al. Autoantibodies to thrombopoietin and the thrombopoietin receptor in patients with immune thrombocytopenia. Br J Haematol. 2018;181(2):234\u201341.","journal-title":"Br J Haematol"},{"issue":"1","key":"9454_CR15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/bjh.12480","volume":"163","author":"CGJ McKenzie","year":"2013","unstructured":"McKenzie CGJ, Guo L, Freedman J, et al. Cellular immune dysfunction in immune thrombocytopenia (ITP). Br J Haematol. 2013;163(1):10\u201323.","journal-title":"Br J Haematol"},{"issue":"2","key":"9454_CR16","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1538-7836.2008.03161.x","volume":"7","author":"M Kuwana","year":"2009","unstructured":"Kuwana M, Okazaki Y, Ikeda Y. Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura. J Thromb Haemost. 2009;7(2):322\u20139.","journal-title":"J Thromb Haemost."},{"issue":"5","key":"9454_CR17","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3324\/haematol.2014.115634","volume":"100","author":"M Iraqi","year":"2015","unstructured":"Iraqi M, Perdomo J, Yan F, et al. Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro. Haematologica. 2015;100(5):623\u201332.","journal-title":"Haematologica"},{"issue":"2","key":"9454_CR18","first-page":"157","volume":"33","author":"AC Cordeiro","year":"2008","unstructured":"Cordeiro AC, Isenberg DA. Novel therapies in lupus - focus on nephritis. Acta Reumatol Port. 2008;33(2):157\u201369.","journal-title":"Acta Reumatol Port"},{"issue":"11","key":"9454_CR19","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1136\/archdischild-2020-321211","volume":"106","author":"R Sinha","year":"2021","unstructured":"Sinha R, Agrawal N, Xue Y, et al. Use of rituximab in paediatric nephrology. Arch Dis Child. 2021;106(11):1058\u201365.","journal-title":"Arch Dis Child"},{"issue":"5","key":"9454_CR20","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jpeds.2006.03.011","volume":"148","author":"JL Huggins","year":"2006","unstructured":"Huggins JL, Brunner HI. Targeting B cells in the treatment of childhood-onset systemic lupus erythematosus. J Pediatr. 2006;148(5):571\u20133.","journal-title":"J Pediatr"},{"issue":"1","key":"9454_CR21","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1542\/peds.2008-2361","volume":"123","author":"S Kumar","year":"2009","unstructured":"Kumar S, Benseler SM, Kirby-Allen M, et al. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus. Pediatrics. 2009;123(1):e159\u201363.","journal-title":"Pediatrics"},{"key":"9454_CR22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jpeds.2017.05.002","volume":"187","author":"I Mahmoud","year":"2017","unstructured":"Mahmoud I, Jellouli M, Boukhris I, et al. Efficacy and safety of rituximab in the management of pediatric systemic lupus erythematosus: a systematic review. J Pediatr. 2017;187:213\u20139.","journal-title":"J Pediatr."},{"issue":"10","key":"9454_CR23","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","volume":"34","author":"G Salles","year":"2017","unstructured":"Salles G, Barrett M, Fo\u00e0 R, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232\u201373.","journal-title":"Adv Ther"},{"issue":"6","key":"9454_CR24","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","volume":"70","author":"MH Buch","year":"2011","unstructured":"Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"9454_CR25","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/art.42092","volume":"74","author":"S Arora","year":"2022","unstructured":"Arora S, Rovin BH. Expert perspective: an approach to refractory lupus nephritis. Arthritis Rheumatol. 2022;74(6):915\u201326.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"9454_CR26","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nrneph.2012.289","volume":"9","author":"A Sinha","year":"2013","unstructured":"Sinha A, Bagga A. Rituximab therapy in nephrotic syndrome: implications for patients\u2019 management. Nat Rev Nephrol. 2013;9(3):154\u201369.","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"9454_CR27","doi-asserted-by":"crossref","first-page":"e12587","DOI":"10.1002\/rth2.12587","volume":"5","author":"EM Harris","year":"2021","unstructured":"Harris EM, Hillier K, Al-Samkari H, et al. Response to rituximab in children and adults with immune thrombocytopenia (ITP). Res Pract Thromb Haemost. 2021;5(6):e12587.","journal-title":"Res Pract Thromb Haemost"},{"key":"9454_CR28","first-page":"9992086","volume":"2021","author":"Y Dong","year":"2021","unstructured":"Dong Y, Yue M, Hu M. The efficacy and safety of different dosages of rituximab for adults with immune thrombocytopenia: a systematic review and meta-analysis. Biomed Res Int. 2021;2021:9992086.","journal-title":"Biomed Res Int"},{"issue":"10","key":"9454_CR29","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s00296-020-04668-4","volume":"40","author":"O Ilizaliturri-Guerra","year":"2020","unstructured":"Ilizaliturri-Guerra O, Uriarte-Botello R, Pineda-Sic R\u00c1, et al. Low-dose rituximab therapy in steroid-refractory thrombocytopenia due to systemic lupus erythematosus. Rheumatol Int. 2020;40(10):1717\u201324.","journal-title":"Rheumatol Int"},{"issue":"4","key":"9454_CR30","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/ajh.26473","volume":"97","author":"X Ni","year":"2022","unstructured":"Ni X, Li D, Yuan C, et al. Single-dose versus low-dose rituximab in corticosteroid-resistant or relapsed ITP: a multicenter, randomized, controlled study. Am J Hematol. 2022;97(4):440\u20137.","journal-title":"Am J Hematol"},{"issue":"3","key":"9454_CR31","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/sj.ki.5002663","volume":"73","author":"P Bhat","year":"2008","unstructured":"Bhat P, Radhakrishnan J. B lymphocytes and lupus nephritis: new insights into pathogenesis and targeted therapies. Kidney Int. 2008;73(3):261\u20138.","journal-title":"Kidney Int"},{"key":"9454_CR32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.coi.2021.05.011","volume":"71","author":"E McAllister","year":"2021","unstructured":"McAllister E, Jellusova J. BAFF signaling in B cell metabolism. Curr Opin Immunol. 2021;71:69\u201374.","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"9454_CR33","doi-asserted-by":"crossref","first-page":"102736","DOI":"10.1016\/j.autrev.2020.102736","volume":"20","author":"T M\u00f6ckel","year":"2021","unstructured":"M\u00f6ckel T, Basta F, Weinmann-Menke J, et al. B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in systemic lupus erythematosus (SLE). Autoimmun Rev. 2021;20(2):102736.","journal-title":"Autoimmun Rev"},{"issue":"7","key":"9454_CR34","doi-asserted-by":"crossref","first-page":"e1399","DOI":"10.1002\/cti2.1399","volume":"11","author":"P Xu","year":"2022","unstructured":"Xu P, Shao X, Ou Y, et al. Neutrophils contribute to elevated BAFF levels to modulate adaptive immunity in patients with primary immune thrombocytopenia by CD62P and PSGL1 interaction. Clin Transl Immunology. 2022;11(7):e1399.","journal-title":"Clin Transl Immunology"},{"issue":"14","key":"9454_CR35","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2018-02-832089","volume":"131","author":"J Tellier","year":"2018","unstructured":"Tellier J. BAFF bestows longevity on splenic plasma cells. Blood. 2018;131(14):1500\u20131.","journal-title":"Blood"},{"issue":"1","key":"9454_CR36","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1172\/JCI65689","volume":"123","author":"M Mah\u00e9vas","year":"2013","unstructured":"Mah\u00e9vas M, Patin P, Huetz F, et al. B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells. J Clin Invest. 2013;123(1):432\u201342.","journal-title":"J Clin Invest"},{"issue":"589","key":"9454_CR37","doi-asserted-by":"crossref","first-page":"eabc3961","DOI":"10.1126\/scitranslmed.abc3961","volume":"13","author":"E Crickx","year":"2021","unstructured":"Crickx E, Chappert P, Sokal A, et al. Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia. Sci Transl Med. 2021;13(589):eabc3961.","journal-title":"Sci Transl Med"},{"issue":"10","key":"9454_CR38","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1182\/blood-2003-09-3109","volume":"103","author":"JI Ellyard","year":"2004","unstructured":"Ellyard JI, Avery DT, Phan TG, et al. Antigen-selected, immunoglobulin-secreting cells persist in human spleen and bone marrow. Blood. 2004;103(10):3805\u201312.","journal-title":"Blood"},{"issue":"11","key":"9454_CR39","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/art.11299","volume":"48","author":"KP Baker","year":"2003","unstructured":"Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48(11):3253\u201365.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"9454_CR40","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2020-217101","volume":"79","author":"HI Brunner","year":"2020","unstructured":"Brunner HI, Abud-Mendoza C, Viola DO, et al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020;79(10):1340\u20138.","journal-title":"Ann Rheum Dis"},{"key":"9454_CR41","doi-asserted-by":"crossref","first-page":"1067721","DOI":"10.3389\/fimmu.2022.1067721","volume":"13","author":"D Wang","year":"2022","unstructured":"Wang D, Shan C, Liu J, et al. Efficacy and safety of belimumab for the treatment of refractory childhood-onset systemic lupus erythematosus: a single-center, real-world, retrospective study. Front Immunol. 2022;13:1067721.","journal-title":"Front Immunol"},{"issue":"3","key":"9454_CR42","doi-asserted-by":"crossref","first-page":"e025687","DOI":"10.1136\/bmjopen-2018-025687","volume":"9","author":"YKO Teng","year":"2019","unstructured":"Teng YKO, Bruce IN, Diamond B, et al. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. BMJ Open. 2019;9(3):e025687.","journal-title":"BMJ Open"},{"issue":"12","key":"9454_CR43","doi-asserted-by":"crossref","first-page":"e032569","DOI":"10.1136\/bmjopen-2019-032569","volume":"9","author":"A Jones","year":"2019","unstructured":"Jones A, Muller P, Dore CJ, et al. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. BMJ Open. 2019;9(12):e032569.","journal-title":"BMJ Open"},{"issue":"9","key":"9454_CR44","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.3324\/haematol.2020.259481","volume":"106","author":"M Mah\u00e9vas","year":"2021","unstructured":"Mah\u00e9vas M, Azzaoui I, Crickx E, et al. Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial. Haematologica. 2021;106(9):2449\u201357.","journal-title":"Haematologica"},{"issue":"6","key":"9454_CR45","first-page":"1056","volume":"35","author":"G De Marchi","year":"2017","unstructured":"De Marchi G, Quartuccio L, Bond M, et al. Efficacy of belimumab for the long-term maintenance therapy of thrombocytopenia in systemic lupus erythematosus. Clin Exp Rheumatol. 2017;35(6):1056.","journal-title":"Clin Exp Rheumatol"},{"key":"9454_CR46","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1749-6632.2009.04804.x","volume":"1173","author":"J Polido-Pereira","year":"2009","unstructured":"Polido-Pereira J, Ferreira D, Rodrigues AM, et al. Rituximab use in pediatric autoimmune diseases: four case reports. Ann N Y Acad Sci. 2009;1173:712\u201320.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"9454_CR47","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/rheumatology\/keg469","volume":"43","author":"R ten Cate","year":"2004","unstructured":"ten Cate R, Smiers FJ, Bredius RGM, et al. Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus. Rheumatology (Oxford). 2004;43(2):244.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"9454_CR48","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1177\/0961203315578764","volume":"24","author":"M Olfat","year":"2015","unstructured":"Olfat M, Silverman ED, Levy DM. Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus. Lupus. 2015;24(9):966\u201372.","journal-title":"Lupus"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-024-09454-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-024-09454-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-024-09454-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T23:18:59Z","timestamp":1719875939000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-024-09454-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,27]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["9454"],"URL":"https:\/\/doi.org\/10.1007\/s12026-024-09454-z","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,27]]},"assertion":[{"value":"24 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Second Hospital of Jilin University (no. 2018198) and adhered to the Helsinki Declaration guidelines. Verbal informed consent was obtained prior to the interview.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest\u00a0"}}]}}